Scientists Debate Race, Genetics, and “Ethnic Medicine”

Scientists Debate Race, Genetics, and “Ethnic Medicine”
By Kevin Davies
Bio-IT World (online)

(10/29/04)—A leading geneticist warned that approval of BiDil, which has been proclaimed as the first “ethnic medicine,” would be premature without pharmacogenetic evaluation to validate reports of its enhanced effectiveness in African-Americans.

Speaking at the American Society of Human Genetics conference in Toronto, David Goldstein, University of College London geneticist, said: “If the [FDA] is seriously going to think about approving BiDil, they should first require a very substantial and serious pharmacogenetic effort to see if genetic determinants… might explain the [population] difference, and to search for environmental determinants, before you race forward for this medicine for one particular ethnic group.”

Leave a Reply

Your email address will not be published. Required fields are marked *